RecruitingPHASE2INTERVENTIONAL
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Sponsor:
- SCRI Development Innovations, LLC
- Conditions:
- Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
- Enrollment:
- 100
- Started:
- Aug 2025
NCT06974786